RARA Antibody

Datasheet
Code CSB-RA019338A0HU
Size US$350
Image
  • IHC image of CSB-RA019338A0HU diluted at 1:155 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. P10276
Target Names RARA
Alternative Names NR1B1 antibody; Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein antibody; Nuclear receptor subfamily 1 group B member 1 antibody; Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form antibody; RAR alpha antibody; RAR antibody; RAR-alpha antibody; rara antibody; RARA_HUMAN antibody; RARalpha antibody; RARalpha1 antibody; Retinoic acid nuclear receptor alpha variant 1 antibody; Retinoic acid nuclear receptor alpha variant 2 antibody; Retinoic acid receptor alpha antibody; Retinoic acid receptor alpha polypeptide antibody
Species Reactivity Human
Immunogen A synthesized peptide derived from human RARA
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Clonality Monoclonal
Isotype Rabbit IgG
Purification Method Affinity-chromatography
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form Liquid
Tested Applications ELISA, IHC
Recommended Dilution
Application Recommended Dilution
IHC 1:50-1:200
Protocols ELISA Protocol
Immunohistochemistry (IHC) Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence of ligand, the RXR-RAR heterodimers associate with a multiprotein complex containing transcription corepressors that induce histone acetylation, chromatin condensation and transcriptional suppression. On ligand binding, the corepressors dissociate from the receptors and associate with the coactivators leading to transcriptional activation. RARA plays an essential role in the regulation of retinoic acid-induced germ cell development during spermatogenesis. Has a role in the survival of early spermatocytes at the beginning prophase of meiosis. In Sertoli cells, may promote the survival and development of early meiotic prophase spermatocytes. In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity). Regulates expression of target genes in a ligand-dependent manner by recruiting chromatin complexes containing KMT2E/MLL5. Mediates retinoic acid-induced granulopoiesis.
Gene References into Functions
  1. Semiquantitative and quantitative analyses of the markers RARA and CRABP2 indicate their potential as biomarkers for tumor progression and their participation in nephroblastoma tumorigenesis PMID: 29378601
  2. The level of RARalpha gene expression as a potential prognostic factor in the pathogenesis of multiple myeloma. PMID: 29119395
  3. The data demonstrate that RARalpha drives integrin beta7-dependent adhesion and CCR9-mediated chemotaxis in CTCL cells. PMID: 28370539
  4. Silencing of PML-RAR and RARalpha2 results in similar increases in the constitutive expression of several granulocytic differentiation markers. PMID: 27419624
  5. RARA drives cyclin-dependent kinase expression, G1-S transition, and cell growth in T-cell lymphoma. PMID: 28412739
  6. Demonstrate that RARalpha was frequently elevated in gastric carcinoma and exerted oncogenic properties via positive feedback loop of IL-1beta/Akt/RARalpha/Akt signaling. PMID: 28035062
  7. Our findings unveil a novel essential oncogenic activity of PML/RARA in Acute promyelocitic leukemia PMID: 27626703
  8. Findings reveal a previously unrecognized role of c-Myc as a potential ceRNA for PML/RARalpha in acute promyelocytic leukemia. PMID: 27486764
  9. RARalpha regulates Arp2/3-mediated actin cytoskeletal dynamics through a non-genomic signaling pathway PMID: 26848712
  10. It has been shown that the AP-1 family member JunB and retinoic acid receptor alpha (RARa) mediate catalase transcriptional activation and repression, respectively, by controlling chromatin remodeling through a histone deacetylases-dependent mechanism. PMID: 27591797
  11. Work identifies the TP53 tumor suppressor as a novel target through which NPM1-RARA impacts leukemogenesis. PMID: 26754533
  12. Dual small interfering RNA (siRNA) silencing of RARalpha and RARgamma reversed RA blockade of P4-induced CK5. Using promoter deletion analysis, we identified a region 1.1 kb upstream of the CK5 transcriptional start site that is necessary for P4 activation and contains a putative progesterone response element (PRE PMID: 28692043
  13. High RARA expression is associated with acute myeloid leukemia. PMID: 28416638
  14. Data suggest that the binding of Z-10 to RXRalpha inhibited the interaction of RXRalpha with PML-RARalpha, leading to Z-10's selective induction of PML-RARalpha degradation. PMID: 28129653
  15. PML-RARa bcr1 fusion is not responsible for colorectal tumor development. PMID: 22167334
  16. overexpression of NLS-RARalpha promoted the proliferation of APL cells and inhibited their differentiation via the PI3K/AKT signaling pathway. PMID: 27840989
  17. r study demonstrated that ATRA cound promote differentiation while inhibit proliferation of acute promyelocytic leukemia NB4 cells via activating p38a protein after recruiting p38a-combinded NLS-RARa, while NLS-RARa could inhibit the effects of ATRA in the process. PMID: 27499693
  18. Low expression of RARalpha was independently associated with worse progression-free survival following platinum-based chemotherapy of advanced Non-small cell lung cancer. PMID: 27306217
  19. The classical counterpart of RARalpha, retinoid X receptor alpha (RXRalpha), was down-regulated in both cytoplasm and nucleus of A549 cells upon atRA addition. PMID: 26818829
  20. RAI1 polymorphisms rs4925102 and rs9907986 are predicted to disrupt the binding of retinoic acid RXR-RAR receptors and the transcription factor DEAF1, respectively, in Smith-Magenis and Potocki-Lupski syndromes patients. PMID: 26743651
  21. Data suggest that hematopoietically expressed homeobox protein (HHEX) downmodulation by promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein (PML-RARalpha) is a key event during acute promyelocytic leukemia (APL) pathogenesis. PMID: 27052408
  22. ATRA dramatically down regulated RARalpha protein levels and led to more DNA damage and ultimately resulted in the synergism of these two agents PMID: 26728137
  23. NPM-RAR binding to TRADD selectively inhibits caspase activation, while allowing activation of NFkappaB and JNK PMID: 25791120
  24. Suggest a novel role of PCGF2 in arsenic trioxide-mediated degradation of PML-RARA that PCGF2 might act as a negative regulator of UBE2I via direct interaction. PMID: 27030546
  25. down-regulation of the level of RAR alpha leads to increased expression of VDR in acute myeloid leukemia. PMID: 26969398
  26. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARalpha protein degradation in acute promyelocytic leukemia. PMID: 26213848
  27. Novel insight into the functional difference of acquired mutations of PML-RARA both in vitro and in the clinical setting. PMID: 26537301
  28. our findings challenge the predominant model in the field and we propose that PML/RARA initiates leukemia by subtly shifting cell fate decisions within the promyelocyte compartment. PMID: 26088929
  29. RARalpha might be involved in the pathogenesis of varicocele as its expression is reduced in pathologic samples. PMID: 24992177
  30. The PML-region mutations were associated with response to Arsenic trioxide-based therapy (P < 0.0001), number of relapses (P = 0.001), and early relapse (P = 0.013)in acute promyelocytic leukemia patients. PMID: 26294332
  31. Data show that the tumor suppressor RASSF1A is a direct target of the PML/RARalpha-regulated microRNAs miR-181a/b cluster. PMID: 26041820
  32. These results suggest that overexpression of RARA enhances malignant transformation during mammary tumorigenesis. PMID: 25300573
  33. E2F1 is found to downregulate retinoic acid receptor alpha (RARalpha), a key factor determines the effectiveness of all-trans retinoic acid. PMID: 24608861
  34. bortezomib impairs the UPS that controls normal protein homeostasis by causing excessive accumulation of PML-RARA augmenting ER stress and leading to acute promyelocytic leukemia cell death PMID: 26026090
  35. CDKN2D repression by PML/RARalpha disrupts both cell proliferation and differentiation in the pathogenesis of acute promyelocytic leukemia. PMID: 25275592
  36. These results indicate that NPM-RAR, not RAR-NPM, is the prime mediator of myeloid differentiation arrest in t(5;17) APL. PMID: 23927396
  37. This study identifies a novel mechanism through which NPM-RAR affects leukemogenesis PMID: 25033841
  38. Data indicate that retinoic acid receptor (RAR) is crucial for regulating sodium taurocholate cotransporting polypeptide (NTCP) expression that determines permissiveness to hepatitis B virus (HBV) infection. PMID: 25550158
  39. Human miR-138 promotes tau phosphorylation by directly targeting the RARA and the associated GSK-3beta pathway. PMID: 25680531
  40. Down-regulation of NLS-RARalpha expression inhibited the proliferation and induced the differentiation of HL-60 cells. On the contrary, over-expression of NLS-RARa promoted proliferation and reduced the ATRA-induced differentiation of HL-60 cells. PMID: 24516348
  41. PML-RARalpha cooperates with HIF-1alpha to activate a pro-leukemogenic program. PMID: 24711541
  42. Results show that UTX interacts with the retinoic acid receptor alpha (RARalpha) and this interaction is essential for proper differentiation of leukemic U937 cells in response to retinoic acid. PMID: 25071154
  43. SUMO-1 modification of RARA is a potent mechanism for balancing proliferation and differentiation by controlling the stability of RARA in cancer cells. PMID: 24819975
  44. The current status of knowledge indicates that there might be inter- or overlapping actions between PPARg and RARs, and there might be an association of PPARg/RARs(RARa, RARb, and RARg) with renal diseases PMID: 24050824
  45. PML/RARalpha suppresses PU.1-dependent activation of the proteasome immunosubunits in acute promyelocytic leukemia. PMID: 23770850
  46. The presence of a mutation in the arsenic-binding domain of PML-RARA led to arsenic resistance in patients with acute promyelocytic leukemia. PMID: 24806185
  47. The objective was to describe the frequency of molecular subtypes of PML/RARalpha in patients with acute promyelocytic leukemia (APL) and their distribution according to risk of recurrence and cytomorphology PMID: 23612809
  48. provide evidence for the existence of a functional ternary complex containing TDG, CBP and activated RARalpha PMID: 24394593
  49. Differences in RAR and RXR subtype mRNA expression patterns in various PTCs may contribute to the immunochemistry data available, and may thus find exploitation in clinical oncology, particularly in the differential diagnosis of thyroid neoplasms. PMID: 23969901
  50. The tumor suppressor gene DAPK2 is induced by the myeloid transcription factors PU.1 and C/EBPalpha during granulocytic differentiation but repressed by PML-RARalpha in APL. PMID: 24038216
  51. OSTbeta is a target of RARalpha-mediated (by binding to DR5 response element) gene regulation pathways PMID: 24264050
  52. RXR interaction is necessary for NPM-RAR-mediated myeloid maturation arrest. PMID: 24183235
  53. Retinoic acid receptor alpha may be a novel therapeutic target and a predictive factor for estrogen receptor alpha-positive breast cancer patients treated with adjuvant tamoxifen. PMID: 23868472
  54. Data indicate antagonism to retinoic acid receptor alpha (RARalpha) for both synthesized chromene analog compounds. PMID: 23474897
  55. RARalpha2 has a role in determining myeloma stem cell features in mouse and human cells PMID: 23847194
  56. an association between polymorphisms of RARA gene and some of some common adverse effects of oral isotretinoin in acne patients PMID: 23782583
  57. RARalpha-PLZF fusion protein inhibits myeloid cell differentiation through interactions with C/EBPalpha tethered to DNA in acute promyelocytic leukemia. PMID: 23898169
  58. CTBP2 is a transcriptional cofactor for RXR-alpha/RAR-alpha. PMID: 23775127
  59. STAT5-RARA positive acute promyelocytic leukemia variant is unresponsive to both all trans retinoic acid and arsenic trioxide. PMID: 23271512
  60. Studies indicate that initiation of leukemogenesis by PML-RARalpha occurs independently from DNA methylation. PMID: 23448850
  61. detection of double-stranded polymerase chain reaction (PCR) products of PML/RARalpha fusion gene in acute promyelocytic leukemia (APL) PMID: 23064710
  62. Results define PARG as a coactivator regulating chromatin remodeling during retinoic acid receptor-dependent gene expression. PMID: 23102699
  63. The RAR-dependent and Pol III-dependent DR2 Alu transcriptional events in stem cells functionally complement the Pol II-dependent neuronal transcriptional program. PMID: 23064648
  64. analysis of a cryptic PML-RARA translocation in a patient with acute promyelocytic leukemia [case report] PMID: 22982005
  65. a novel paradigm in which a fraction of the cellular RARalpha pool is present in membrane lipid rafts, where it forms complexes with G protein alpha Q (Galphaq) in response to RA PMID: 22056876
  66. HK3 is: (1) directly activated by PU.1, (2) repressed by PML-RARA, and (3) functionally involved in neutrophil differentiation and cell viability of acute promyelocytic leukemia cells. PMID: 22498738
  67. Data show that RORalpha is mainly located in human Jurkat T-cell nucleus, and it is co-immunoprecipitated with melatonin. PMID: 21736617
  68. APL lacking an RARalpha rearrangement may possess an alternative mechanism mediating the differentiation block that causes APL. PMID: 22181564
  69. Coregulator exchange and chromatin binding affect retinoic acid receptor mobility. PMID: 22045737
  70. These findings suggest that TRIM32 functions as one of the coactivators for RARalpha-mediated transcription in acute promyelogenous leukemia cells. PMID: 22182411
  71. BCOR is a fusion partner of RARA in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia. BCOR-RARA possesses common features with other RARA fusion proteins. PMID: 20807888
  72. Data show that TEL as a transcriptional repressor of Retinoic acid receptor (RAR) signaling by its direct binding to both RAR and its dimerisation partner, the retinoid x receptor (RXR) in a ligand-independent fashion. PMID: 21949683
  73. The present study further demonstrated that GRP75 translocates into the nucleus and physically interacts with retinoid receptors (RARalpha and RXRalpha) to augment retinoic acid-elicited neuronal differentiation. PMID: 22022577
  74. investigation of DNA breakpoints in PML-RARalpha V-form fusion transcripts in 7 Chinese acute promyelocytic leukemia patients (out of total of 134 APL patients); in 5 of these cases, the V-form transcripts were unique (i.e., not described previously) PMID: 21934296
  75. PMLRARalpha binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. PMID: 21803845
  76. Data indicate that PML-RARA (PR)-WT in the soluble fraction was transferred to the insoluble fraction after treatment with AsO, but PR-B/L-mut was stably detected in fractions both with and without AsO. PMID: 21613260
  77. Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARalpha oncoprotein PMID: 21187718
  78. both CD1d and CD1c are upregulated by RARalpha signaling in human B cells PMID: 21451111
  79. physiologic PML-RARA expression was sufficient to direct a hematopoietic progenitor self-renewal program in vitro and in vivo PMID: 21364283
  80. Phenotype onset is correlated with NuMA-RARalpha copy number; mice with higher copy number developing disease later than those with lower copy number. PMID: 21255834
  81. Depletion of S100A10 by RNA interference effectively blocked the enhanced fibrinolytic activity observed after induction of the PML-RAR-alpha oncoprotein PMID: 21310922
  82. RARa-mediated signaling acts as an endogenous protective pathway to slow the progression of kidney disease, and selective activation of the RARa receptor may be a promising treatment option for patients with HIV-associated nephropathy. PMID: 21150871
  83. data indicate that JNK activation by oxidative stress suppresses retinoid signaling through proteasomal degradation of RARalpha PMID: 21272161
  84. One variant in the RARA gene (rs12051734), three variants in the RARB gene (rs6799734, rs12630816, rs17016462), and one variant in the RARG gene (rs3741434) were found to be statistically significant at p < 0.05 as risk factors for meningomyelocele. PMID: 21254357
  85. Rara haploinsufficiency (like Pml haploinsufficiency and RARA-PML) can cooperate with PML-RARA to influence the pathogenesis of APL in mice, but that PML-RARA is the t(15;17) disease-initiating mutation. PMID: 21190992
  86. New insights that arose from these studies, in particular focussing on newly identified PML-RARalpha target genes, its interplay with RXR and deregulation of epigenetic modifications. PMID: 21245861
  87. RAR, RXR and VDR are expressed in human fetal pancreatic progenitor cells. PMID: 20354914
  88. Tribles homolog 1 (Trib1) functions as a negative regulator of Retinoic acid receptor-alpha. PMID: 21053424
  89. CART1 might be a cytoplasmic, testis-specific derepressor of RAR PMID: 20736163
  90. autophagic degradation contributes significantly both to the basal turnover as well as the therapy-induced proteolysis of PML/RARA PMID: 20574048
  91. alternative splicing of PML/RARalpha transcripts might be involved in nonsense-mediated decay PMID: 19863682
  92. RARA amplification in hematologic malignancies may serve as an independent prognostic factor. PMID: 20804918
  93. RARA breakpoints are associated with acute promyelocytic leukemia. PMID: 20544846
  94. The basal repressive activity of RAR is conferred by an extended beta-strand that forms an antiparallel beta-sheet with specific corepressor residues. PMID: 20543827
  95. PML-RARalpha/RXR functions as a local chromatin modulator and that specific recruitment of histone deacetylase activities to genes important for hematopoietic differentiation, RAR signaling, and epigenetic control is crucial to its transforming potential. PMID: 20159609
  96. Selective targeting of PU.1-regulated genes by PML/RARalpha is a critical mechanism for the pathogenesis of acute promyelocytic leukemia(APL). PMID: 20159610
  97. Role of RARA in differentiation of human mesenchymal stem cells is reported. PMID: 20185965
  98. We studied 21 PML-RARA positive/RARA-PML negative cases by bubble PCR and multiplex long template PCR to identify the genomic breakpoints. PMID: 20155840
  99. Retinoic acid-suppressed phosphorylation of RARalpha induces FGF8f expression to mediate differentiation response pathway in U2OS osteosarcoma cells. PMID: 20190807
  100. PML/RARalpha transactivates the TF promoter through an indirect interaction with an element composed of a GAGC motif and the flanking nucleotides, independent of AP-1 binding. PMID: 20133705

Show More

Hide All

Involvement in disease Chromosomal aberrations involving RARA are commonly found in acute promyelocytic leukemia. Translocation t(11;17)(q32;q21) with ZBTB16/PLZF; translocation t(15;17)(q21;q21) with PML; translocation t(5;17)(q32;q11) with NPM. The PML-RARA oncoprotein requires both the PML ring structure and coiled-coil domain for both interaction with UBE2I, nuclear microspeckle location and sumoylation. In addition, the coiled-coil domain functions in blocking RA-mediated transactivation and cell differentiation.
Subcellular Location Nucleus, Cytoplasm
Protein Families Nuclear hormone receptor family, NR1 subfamily
Database Links

HGNC: 9864

OMIM: 180240

KEGG: hsa:5914

STRING: 9606.ENSP00000254066

UniGene: Hs.654583

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved. 鄂ICP备15011166号-1